Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QTJ
|
|||
| Former ID |
DNC000423
|
|||
| Drug Name |
Chloroethylclonidine
|
|||
| Synonyms |
Chloroethylclonidine; Chlorethylclonidine; UNII-3X825O680H; N-(2,6-Dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine; 3X825O680H; 98086-36-3; 1h-imidazol-2-amine, n-[2,6-dichloro-4-[[(2-chloroethyl)methylamino]methyl]phenyl]-4,5-dihydro-; 1H-Imidazol-2-amine, N-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-; Lopac-B-003; AC1Q3UQS; AC1L2XTB; Lopac0_000195; C11H12Cl3N3; SCHEMBL4107963; CHEMBL326967; SCHEMBL18154646; CTK3I7576; PDSP2_000070; ZINC27089957
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H17Cl3N4
|
|||
| Canonical SMILES |
CN(CCCl)CC1=CC(=C(C(=C1)Cl)NC2=NCCN2)Cl
|
|||
| InChI |
1S/C13H17Cl3N4/c1-20(5-2-14)8-9-6-10(15)12(11(16)7-9)19-13-17-3-4-18-13/h6-7H,2-5,8H2,1H3,(H2,17,18,19)
|
|||
| InChIKey |
XFDVJGKSQRUEEM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 77472-95-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10233703, 11110807, 15471003, 26755658, 44434528, 47285790, 47350430, 47954381, 50065430, 50110970, 51618293, 57337944, 85209019, 90341347, 92098494, 103100301, 103340708, 104373340, 117472294, 124749532, 124879335, 124879336, 129680080, 134339851, 135062207, 135089706, 162755894, 179235756, 198940830, 230066265, 241137222
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Agonist | [1] |
| Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Agonist | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.